Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease by Jiang, Hong et al.
RESEARCH ARTICLE Open Access
Elevated CSF levels of TACE activity and soluble
TNF receptors in subjects with mild cognitive







4 and Yong Shen
1,5*
Abstract
We recently reported that expression levels of tumor necrosis factor (TNF) receptors, TNFR1 and TNFR2, are
significantly changed in the brains and cerebrospinal fluid (CSF) with Alzheimer’s disease (AD). Moreover, we also
found that, in an Alzheimer’s mouse model, genetic deletion of TNF receptor (TNFR1) reduces amyloid plaques and
amyloid beta peptides (Ab) production through b-secretase (BACE1) regulation. TNF-a converting enzyme (TACE/
ADAM-17) does not only cleave pro- TNF-a but also TNF receptors, however, whether the TACE activity was
changed in the CSF was not clear. In this study, we examined TACE in the CSF in 32 AD patients and 27 age-
matched healthy controls (HCs). Interestingly, we found that TACE activity was significantly elevated in the CSF
from AD patients compared with HCs. Furthermore, we also assayed the CSF levels of TACE cleaved soluble forms
of TNFR1 and TNFR2 in the same patients. We found that AD patients had higher levels of both TACE cleaved
soluble TNFR1 (sTNFR1) and TNFR2 (sTNFR2) in the CSF compared to age- and gender-matched healthy controls.
Levels of sTNFR1 correlated strongly with the levels of sTNFR2 (rs = 0.567-0.663, p < 0.01). The levels of both
sTNFR1 and sTNFR2 significantly correlated with the TACE activity (rs = 0.491-0.557, p < 0.05). To examine if
changes in TACE activity and in levels of cleaved soluble TNFRs are an early event in the course of AD, we
measured these molecules in the CSF from 47 subjects with mild cognitive impairment (MCI), which is considered
as a preclinical stage of AD. Unexpectedly, we found significantly higher levels of TACE activity and soluble TNFRs
in the MCI group than that in AD patients. These results suggest that TACE activity and soluble TNF receptors may
be potential diagnostic candidate biomarkers in AD and MCI.
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Introduction
Extensive evidence supports the concept that neuroin-
flammation plays a significant role in the neuropatho-
genesis of Alzheimer’s disease (AD) [1-7]. Tumor
necrosis factor-a (TNF-a) is one of the major inflamma-
tory cytokines and plays a key role in AD [8] by regulat-
ing two TNF receptors, TNFR1 and TNFR2, through
various signal transduction pathways, which finally con-
verge to a common mechanism of neuronal death. We
recently reported [9] that the expression levels of the
two TNF receptors are significantly changed in AD
brain tissues; specifically TNFR1 is increased whereas
TNFR2 is significantly decreased in AD brains. Our stu-
dies on double transgenic mice demonstrate that dele-
tion of TNFR1 in Alzheimer transgenic APP23 mice
results in reduction of brain amyloid plaques and Ab
levels [10]. Furthermore, clinical evidence supports the
concept that inhibiting the expression of TNF-a may
result in cognitive improvement in AD patients [11,12].
TNF-a functions through binding to its two receptor
subtypes, TNFR1 and TNFR2 [8]. Interestingly, studies
have shown that both TNFR1 and TNFR2 can be shed
from the cell surface with TACE/ADAM17 to become
soluble forms [13]. TACE is a transmembrane disinte-
grin metalloprotease that cleaves precursor TNF-a to
generate soluble, secreted TNF-a in macrophages and
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released forms of TNF are biologically active, but full
inflammatory responses require the soluble form in at
least some situations [16]. When TNFRs are shed by
TACE, TNFR-mediated TNF-a signaling might be inter-
rupted. Untill now, there are no reports regarding solu-
ble TNFRs act as dominant-negative competitors to
their receptor counterparts. Recently, soluble TNF
receptors have been detected in CSF from preclinical
AD patients [17]. However, it was not known whether
TACE/ADAM-17 activity in the CSF would be changed.
If TACE/ADAM17 is being shed from the brain cell
membranes and leaks into the CSF after cleavage of the
two TNF receptors, we would be able to detect TACE
activity in the CSF throughout different stages of AD.
Based on the evidence and rationales described above,
we examined levels of TACE, and soluble TNF receptors
in the CSF from AD patients and MCI subjects.
Materials and methods
Subjects
CSF samples were obtained from total 103 patients in
two independent clinical research center: the Alzheimer
Memorial Center, Department of Psychiatry, Ludwig-
Maximilian University in Germany and the Department
of Clinical Neuroscience, University of Goteborg, Sahlg-
ren’s University Hospital, Sweden. A total of 103 indivi-
duals were recruited from the above centers, 32
probable AD patients, 44 MCI subjects and 27 age-
matched healthy individuals. As we described previously
[18,19], diagnosis of AD was made according to the
National Institute of Neurological and Communicative
Disorders and Stroke (NINCDS-ADRDA) criteria [20],
including the Mini-Mental State Examination (MMSE)
and MCI was diagnosed according to the Petersen cri-
teria [21]. MCI subjects performed 1.5 SD below the
age-adjusted reference average in memory scales, as
assessed using the Consortium to Establish a Registry
for Alzheimer’s Disease (CERAD) cognitive battery [22].
This battery included verbal learning, recognition, and
recall tests; global cognitive function and activities of
daily living were unimpaired. Controls were cognitively
healthy individuals who underwent spinal anesthesia for
surgery of the urinary tract or lower extremities. Psy-
chiatric comorbidity was excluded by means of history,
clinical examination, and Composite International Diag-
nostic Interview [23]. All the controls were cognitively
normal according to Consortium to Establish a Registry
for Alzheimer’s Disease cognitive battery performance
(within 1 SD in all subtests), and the participants had
no complaints of cognitive impairment and had no his-
tory of dementia, did not show any signs of other psy-
chiatric illnesses, and were followed up clinically for 3
years to exclude development of any neurodegenerative
disease. To avoid spinal anesthesia as a potential con-
founding factor when collecting CSF, CSF was obtained
immediately after inserting the needle and just before
application of the anesthetic drug. CSF samples were
obtained at baseline by lumbar puncture in the L3/L4 or
L4/L5 interspace. The CSF samples were gently mixed
to avoid possible gradient effects, centrifuged, and stored
at -80°C pending biochemical analyses, without being
thawn and re-frozen. All the procedures were approved
by the institutional review boards (IRB) of the respective
institutions, and consent forms were signed by the
patients before sample collection.
Assays of soluble TNFR (sTNFR) in the CSF
Both sTNFR1 and sTNFR2 were measured using a com-
mercially available immunoassay according to the
instructions provided by the manufacturer “R&D System”
(Minneapolis, MN, USA). We added 50 μL of assay dilu-
ent to each well, then added 200 μL sample to each well,
incubating for 2 hrs at room temperature. After aspirat-
ing and washing 3 times, 200 μL conjugate were added to
each well and incubated for 2 hrs at room temperature.
After aspirating and washing 3 times, we added 200 μL
substrate solution to each well, incubated 20 min at RT,
protecting from light. At last, we added 50 μLs t o ps o l u -
tion to each well, and read at 450 nm within 30 min. The
detection limit of the assay is 7.8 pg/ml of human recom-
binant sTNFR with an inter-assay variation of < 10%.
Assays of levels of TACE activity
TACE activity was measured using a solution-based
assay. 7.5 μL of CSF was first diluted to 90 μL with run-
ning buffer (1 M Tris HCl, 10 mM ZnCl2). Ten microli-
ter TACE substrate (R&D System, Minneapolis, MN,
USA) was added to a final concentration. The enzymatic
activity was measured using a microplate reader set to
320 nm of the excitation and 405 nm of the emission.
The specific enzymatic activity of TACE is calculated
FU/min.
Statistical analysis
The Statistical Package for Social Sciences (SPSS 11.5
for Windows) was used for statistical comparisons.
Results were presented as mean ± S.E.M. Paired-Sam-
ples T test was used to compare differences between
means in two groups. Spearman’s correlation coefficient
was used for correlation analysis. A probability value of
p < 0.05 was taken to indicate statistical significance.
Results
Levels of TACE activity and sTNFRs in CSF in the different
diagnostic groups
As shown in Table 1, there was no statistically signifi-
cant difference in age between the AD (71.4 ± 7.4) and
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cant difference of age between the AD/MCI and the HC
group (55.6 ± 10) (p < 0.05). There was no difference in
gender distribution among the three groups (p > 0.01).
MMSE scores differed significantly between AD patients
(20.1 ± 4.8) and HC subjects (28.7 ± 1.1) p < 0.001),
MCI patients (26.2 ± 2.2) and HC subjects (p < 0.05),
and AD and MCI patients (p < 0.001).
Interestingly as shown in Figure 1, in MCI, TACE
activity levels (91.2 ± 6.6 FU/min) and sTNFR1 (972.1
± 50.7 pg/mL) did not fall in between AD (TACE: 82.0
± 6.8 FU/min; sTNFR1: 930.9 ± 52.5 pg/mL) and HC
subjects (TACE: 53.1 ± 6.6 FU/min; sTNFR1: 705 ±
66.2 pg/mL) (Table 1). There was a significant differ-
ence in TACE activity levels between AD and HC (df
= 1; p < 0.001), between MCI and HC (df = 1; p <
0.01), and between AD and MCI patients (df = 1; p <
0.05). The sTNFR1 levels in the CSF from both AD
and MCI patients were significantly higher than those
in HC subjects (Paired-Samples T test, p < 0.05).
There was a significant difference in sTNFR1 levels
between AD and MCI (df = 1; p < 0.01), between AD
and HC (df = 1; p < 0.05), and between MCI and HC
(df = 1; p < 0.01). However, sTNFR2 levels in MCI
patients (602.6 ± 38.7) fell into between AD patients
(832.1 ± 54.1 pg/mL) and HC subjects (409.6 ± 130.2
pg/mL). Moreover, there was a significant difference in
sTNFR2 of CSF between MCI patients and HC sub-
jects (p < 0.05), and between AD and HC subjects
(Paired-Samples T test p < 0.001).
Significant correlations between baseline levels of sTNFR1
and sTNFR2 in CSF
In the subjects with MCI, AD patients and HC sub-
jects, there were positive and strong correlations
between sTNFR1 and sTNFR2 in CSF (rs =0 . 5 6 7 -
0.690, p < 0.01; rs = 0.567-0.663, p < 0.01) (Table 2
Figures 2, 3).
Correlations between the baseline levels of sTNFRs and
TACE activity
The levels of both sTNFRs in CSF correlated strongly
with the CSF activity of TACE (rs = 0.491-0.557, p <
0.05) (Table 2 Figures 1, 4, 5).
Table 1 Baseline data in the patients with MCI, AD and







Age (years) 55.6 ± 10.0 71.9 ± 7.1
b 71.4 ± 7.4
b
Sex (M/F) 17/10 23/21 11/21
MMSE at baseline (0-30 p) 28.7 ± 1.1 26.2 ± 2.2
b 20.1 ± 4.8
a
CSF sTNFR1 (pg/mL) 705.0 ± 66.2 972.1 ± 50.7
b 930.9 ± 52.5
b
CSF sTNFR2 (pg/mL) 409.6 ± 130.2 602.6 ± 38.7
b 832.1 ± 54.1
a
CSF TACE activity (FU/min) 53.1 ± 6.6 91.2 ± 6.6
c 82.0 ± 6.8
b
Values are means ± S.D., except as noted otherwise. Abbreviations: AD
patients with stable cognitive functions; MCI: mild cognitive impairment;
Controls, healthy controls, with unimpaired cognition after at least 3 years
follow-up; MMSE, mini-mental state examination; sTNFR, soluble tumor
necrosis factor-a receptor; CSF, cerebrospinal fluid.
a p < 0.001 vs. Controls.
b p < 0.05 vs. Controls.
c p < 0.01 vs. Controls.
Figure 1 The baseline levels of soluble TNF receptors, type I and type 2 (sTNFR1 and sTNFR2) in CSF correlate positively to the TACE
activity in AD patients.
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In the present study, as shown in Table 1, we did see
the age difference between healthy controls and MCI
and healthy controls and AD patients. Although up to
now, based on the published literatures, there is no
direct evidence for a possible impact of age on TACE, it
is possible that aging may contribute to TACE changes
via different mechanisms. In this study, we investigated
TACE and both sTNFR1 and sTNFR2 in the CSF from
AD and MCI patients. Interestingly, the levels of sTNFR
in CSF were significantly increased in the subjects with
AD compared to age and sex-matched healthy controls.
Moreover, the CSF levels of both types of sTNFR in the
AD subjects correlated strongly with TACE activity.
These results suggest that the disease severity may affect
the TACE activity.
Accumulating evidence supports the idea that neuroin-
flammation plays a significant role in the neuropathogen-
esis of AD [24]. Tumor necrosis factor-a (TNF-a)i so n e
of the major inflammatory cytokines produced by acti-
vated astrocytes and microglia. Increasing evidence now
supports the concept that excess TNF-a plays a central
role in AD [8,25]. TNF-a exerts its biological effects by
binding to TNFR1 and TNFR2. Both receptors belong to a
super family of transmembrane receptors that are defined
by a similar cysteine-rich extracellular domain, however,
the intracellular regions of TNFR1 and TNFR2 appear to
be unrelated, suggesting distinct modes of activation of
signal transduction pathways [8,26,27]. TNFR1 is constitu-
tively expressed at low levels on all nucleated cells, TNFR2
has a higher affinity for TNF than TNFR1 and binds TNF
better at lower concentrations [9,28]. It has been proposed
that in advanced stages of AD once extensive amyloid pla-
ques have formed, elevated levels of pro-inflammatory
cytokines, including TNF-a, may inhibit phagocytosis of
toxic Ab species and/or hinder efficient plaque removal by
brain resident microglia [29]. Proinflammatory cytokines
attenuate microglial phagocytosis stimulated by fAb or
complement receptor 3 and argue that this may, in part,
underlie the accumulation of fAb -containing plaques
within the AD brain. The proinflammatory suppression of
fAb -elicited phagocytosis is dependent on nuclear factor
Table 2 Correlations between baseline CSF levels of
soluble TNF receptors and TACE activity
CSF TACE sTNFR1 sTNFR2
Controls sTNFR1 rs = 0.491
b / rs = 0.567
c
sTNFR2 rs = 0.557
c rs = 0.567
c /
MCI sTNFR1 rs = 0.400
c / rs = 0.690
a
sTNFR2 rs = 0.311
b rs = 0.690
a /
AD sTNFR1 rs = 0.541
c / rs = 0.663
a
sTNFR2 rs = 0.508
c rs = 0.663
a /
All data were collected at baseline. Abbreviations: CSF, cerebrospinal fluid;
sTNFR, soluble tumor necrosis factor-a receptor; AD: Alzheimer’s disease; MCI:
mild cognitive impairment; TACE: tumor necrosis factor-a converting enzyme.
a p < 0.001.
b p < 0.05.
c p < 0.01.
Figure 2 The baseline levels of soluble TNF receptors type 1 and type 2 (sTNFR1 and sTNFR2) in CSF correlate positively to the TACE
activity in aged-matched healthy individuals.
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TNFR1 through high affinity binding [9] and signaling
accordingly suppresses Ab degradation by reducing the
expression of insulin degrading enzyme [30] and affects
Ab production through upregulation of BACE expression
[31] and g-secretase activity [32]. In our study, the signifi-
cantly higher levels of sTNFR1 in CSF of the patients with
AD compared to age-matched controls indicated that in
spite of its conversion into soluble forms, the TNFR1 sig-
naling pathway was still existing in the presence of
excessive TNF-a, and may thus contribute to Ab produc-
tion as discussed above. On the other hand, the activation
of the TNFR2 signaling pathway may be neuroprotective
[33]. The elevated levels of sTNFR2 in CSF as shown in
the present study suggest that TNFR2 is deficient as we
recently reported [9], possibly cleaved by TACE. This
impaired TNFR2 signaling pathway might alleviate the
neuroprotective effects and also promote Ab production.
We showed elevated levels of the TACE activity in
CSF. Moreover, there were positive and significant
Figure 3 The baseline levels of soluble TNF receptors, type 1 and type 2 (sTNFR1 and sTNFR2) in CSF correlate positively to the TACE
activity in MCI patients.
Figure 4 The levels of soluble TNF receptor type 1 (sTNFR1) in CSF correlate positively to the soluble TNF receptor type 2 (sTNFR2) in
the CSF between AD patients and aged-matched healthy controls.
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activity in AD. TACE is a metalloprotease-disintegrin
that releases several transmembrane proteins into solu-
ble forms, including TNFR1 and TNFR2 [34,35]. There-
fore, increased TACE activity would contribute to
increased sTNFR as shown in the present study. These
findings are in accordance with other reports that
increased levels of TACE shed more sTNFRs [36,37].
Both but through different regulation mechanisms,
b-( B A C E )a n da-(TACE) secretases contribute to Ab
production. BACE-mediated cleavage of amyloid pre-
cursor protein (APP) at the N terminus of the Ab
sequence is the first step in the generation of Ab and
BACE has been shown to be upregulated in sporadic
AD brains [38,39]. TACE is also responsible for the a-
secretase cleavage of APP [40,41]. Release of sAPPa
precludes the formation of amyloidogenic peptides by
BACE [42]. Although not presented in this study, there
is general consensus that levels of CSF Ab1-42 in AD
are lower than those in ND [43]. The fact that TACE
is increased in the CSF of AD might lead to the
assumption that high TACE activity would parallel
increased sAPPa and reduced Ab levels. However, the
most abundant form of Ab -A b1-40 - is not decreased
in AD, which speaks against a role of TACE activity in
the modulation of CSF Ab levels. The observed reduc-
tion of Ab1-42 in CSF may be related to oligomeriza-
tion and aggregation of Ab1-42 rather than to TACE
activities. Indeed, several independent studies demon-
strate that modifying TACE activity does not affect
APP cleavage by BACE and Ab production [44-47].
This would explain why even increased TACE activity
in AD it doesn’ta l t e rt h eA b production from APP.
This was further supported by other reports that inhi-
bition or knockdown of TACE does not affect sAPP
formation and Ab secretion under normal conditions
[40,48]. TACE might not predominantly cleave APP in
AD and plays a role only in the regulatory component
of the a-secretase processing of APP. Therefore, we
suggest that TACE may predominantly cleave TNFRs
rather than APP, and contribute to upregulation of
BACE and consecutive increase of Ab production
through the TNFR signaling pathway as discussed
above.
Figure 5 The levels of soluble TNF receptor type 1 (sTNFR1) in CSF correlate positively to the soluble TNF receptor type 2 (sTNFR2) in
the CSF among the MCI patients.
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sTNFRs and TACE activity in CSF, as well as correla-
tions between them in patients with AD compared to
age and sex-matched controls. These results further
support the concept that the TNFR signaling pathway
contributes to Ab production and to the subsequent
cytotoxicity in the brain. sTNFRs and TACE may
become valid diagnostics targets to determine AD.
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